文献速递乳腺癌

PERUSE研究最终结果:一线帕妥珠单抗+曲妥珠单抗+紫杉类治疗HER2阳性局部复发/转移性乳腺癌,多变量分析指导预后

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
PubMed 文献 · Ann Oncol · 2021-07-02

PERUSE是一项多中心单臂研究,评估帕妥珠单抗+曲妥珠单抗联合研究者选择的紫杉类(多西他赛、紫杉醇或白蛋白紫杉醇)一线治疗HER2阳性局部复发/转移性乳腺癌的安全性和疗效。共1436例患者,中位随访5.7年,中位无进展生存期20.7个月,中位总生存期65.3个月,安全性与CLEOPATRA一致,紫杉醇可作为多西他赛的替代骨架。

要点

  • 中位总生存期65.3个月,超过5年,与CLEOPATRA研究一致。
  • 紫杉醇与多西他赛疗效相似,可作为替代骨架化疗。
  • HR阳性患者总生存期优于HR阴性患者。

核心结论

  • PERUSE最终结果与CLEOPATRA研究一致,中位总生存期超过5年。
  • 紫杉醇可作为多西他赛的替代骨架化疗。
  • 探索性分析提示风险因素可指导未来试验设计。

研究设计与样本

  • 多中心单臂研究,纳入1436例接受治疗的患者。
  • 患者接受帕妥珠单抗+曲妥珠单抗联合研究者选择的紫杉类(多西他赛、紫杉醇或白蛋白紫杉醇)直至疾病进展或不可耐受毒性。
  • 主要终点为安全性,次要终点包括无进展生存期和总生存期。

主要发现

  • 最常见≥3级不良事件为中性粒细胞减少(10%,主要见于多西他赛)和腹泻(8%)。
  • 中位随访5.7年,总体中位无进展生存期20.7个月(95%CI 18.9-23.1),与HR状态或紫杉类无关。
  • 总体中位总生存期65.3个月(95%CI 60.9-70.9),与紫杉类骨架无关,HR阳性者优于HR阴性者。
  • 探索性分析中,曲妥珠单抗经治且伴内脏转移的患者中位无进展生存期最短(13.1个月),中位总生存期最短(46.3个月)。

临床怎么用

  • 帕妥珠单抗+曲妥珠单抗联合紫杉类是一线标准治疗,紫杉醇可作为多西他赛的替代选择。
  • HR状态和既往曲妥珠单抗暴露及内脏转移可辅助预后分层。

局限性

  • 单臂研究设计,无随机对照比较。
  • 探索性分析结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The phase III CLinical Evaluation Of Pertuzumab And TRAstuzumab (CLEOPATRA) trial established the combination of pertuzumab, trastuzumab and docetaxel as standard first-line therapy for human epidermal growth factor receptor 2 (HER2)-positive locally recurrent/metastatic breast cancer (LR/mBC). The multicentre single-arm PERtUzumab global SafEty (PERUSE) study assessed the safety and efficacy of pertuzumab and trastuzumab combined with investigator-selected taxane in this setting. PATIENTS AND METHODS: Eligible patients with inoperable HER2-positive LR/mBC and no prior systemic therapy for LR/mBC (except endocrine therapy) received docetaxel, paclitaxel or nab-paclitaxel with trastuzumab and pertuzumab until disease progression or unacceptable toxicity. The primary endpoint was safety. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). Prespecified subgroup analyses included subgroups according to taxane, hormone receptor (HR) status and prior trastuzumab. Exploratory univariable analyses identified potential prognostic factors; those that remained significant in multivariable analysis were used to analyse PFS and OS in subgroups with all, some or none of these factors. RESULTS: Of 1436 treated patients, 588 (41%) initially received paclitaxel and 918 (64%) had HR-positive disease. The most common grade ≥3 adverse events were neutropenia (10%, mainly with docetaxel) and diarrhoea (8%). At the final analysis (median follow-up: 5.7 years), median PFS was 20.7 [95% confidence interval (CI) 18.9-23.1] months overall and was similar irrespective of HR status or taxane. Median OS was 65.3 (95% CI 60.9-70.9) months overall. OS was similar regardless of taxane backbone but was more favourable in patients with HR-positive than HR-negative LR/mBC. In exploratory analyses, trastuzumab-pretreated patients with visceral disease had the shortest median PFS (13.1 months) and OS (46.3 months). CONCLUSIONS: Mature results from PERUSE show a safety and efficacy profile consistent with results from CLEOPATRA and median OS exceeding 5 years. Results suggest that paclitaxel is a valid alternative to docetaxel as backbone chemotherapy. Exploratory analyses suggest risk factors that could guide future trial design.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Miles D, Ciruelos E, Schneeweiss A, et al. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication. Ann Oncol. 2021. PMID: 34224826. doi:10.1016/j.annonc.2021.06.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。